GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orchestra BioMed Holdings Inc (NAS:OBIO) » Definitions » Cash Flow from Investing

Orchestra BioMed Holdings (Orchestra BioMed Holdings) Cash Flow from Investing : $60.08 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Orchestra BioMed Holdings Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Orchestra BioMed Holdings spent $0.01 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $23.74 Mil on purchasing investments. It gained $29.61 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Orchestra BioMed Holdings gained $5.86 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Orchestra BioMed Holdings Cash Flow from Investing Historical Data

The historical data trend for Orchestra BioMed Holdings's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orchestra BioMed Holdings Cash Flow from Investing Chart

Orchestra BioMed Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
26.97 13.02 -64.12 10.69

Orchestra BioMed Holdings Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.53 8.12 12.95 33.15 5.86

Orchestra BioMed Holdings Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Orchestra BioMed Holdings's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Orchestra BioMed Holdings's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $60.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orchestra BioMed Holdings  (NAS:OBIO) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Orchestra BioMed Holdings's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $-0.01 Mil. It means Orchestra BioMed Holdings spent $0.01 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Orchestra BioMed Holdings's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Orchestra BioMed Holdings gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Orchestra BioMed Holdings's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Orchestra BioMed Holdings spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Orchestra BioMed Holdings's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Orchestra BioMed Holdings gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Orchestra BioMed Holdings's purchase of investment for the three months ended in Mar. 2024 was $-23.74 Mil. It means Orchestra BioMed Holdings spent {stock_data.stock.currency_symbol}}23.74 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Orchestra BioMed Holdings's sale of investment for the three months ended in Mar. 2024 was $29.61 Mil. It means Orchestra BioMed Holdings gained $29.61 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Orchestra BioMed Holdings's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Orchestra BioMed Holdings paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Orchestra BioMed Holdings's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Orchestra BioMed Holdings paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Orchestra BioMed Holdings's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Orchestra BioMed Holdings paid $0.00 Mil for other investing activities.


Orchestra BioMed Holdings Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Orchestra BioMed Holdings's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Orchestra BioMed Holdings (Orchestra BioMed Holdings) Business Description

Traded in Other Exchanges
N/A
Address
150 Union Square Drive,, New Hope, PA, USA, 18938
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. Orchestra BioMed's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
Executives
George Papandreou officer: See Remarks C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Eric S Fain director ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN MN
Jason Aryeh director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
David P Hochman director, officer: See Remarks 15 WESTON HILL RD., RIVERSIDE CT 06878
Joshua Aiello officer: Principal Accounting Officer 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Yuval Mika officer: See Remarks 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Pamela Ann Connealy director 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Darren Sherman director, officer: See Remarks C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Rose Eric A Md director 161 FORT WASHINGTON AVENUE, 7TH FLOOR, NEW YORK NY 10032
Andrew Lawrence Taylor officer: Chief Financial Officer C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
William Reed Little officer: See Remarks C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Plc Medtronic 10 percent owner 20 ON HATCH, LOWER HATCH STREET, DUBLIN L2 2
Michael Kaswan officer: Chief Financial Officer KBL HEALTHCARE ACQUISITION CORP II, 645 MADISON AVENUE, NEW YORK NY 10022
Geoffrey Wade Smith director 6740 SHADY OAK ROAD, EDEN PRAIRIE MN 55344
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014